Aprea Therapeutics (APRE) vs NeuroSense Therapeutics (NRSN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Aprea Therapeutics is the larger company by market cap ($7.6 million vs $6.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APRE | NRSN |
|---|---|---|
| Share price | $0.6044 | $3.66 |
| Market cap | $7.61M | $6.94M |
| 1-day change | +8.28% | -2.14% |
| EPS (TTM) | $-0.95 | $-47.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.69 | $26.64 |
| 52-week low | $0.548 | $3.56 |
| Distance from 52-week high | -64.24% | -86.26% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +517.14% | +2559.29% |
| Average volume | 280.14K | 21.29K |
| Shares outstanding | 12.59M | 1.90M |
| Employees | 8 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aprea Therapeutics
APRE stock →Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About NeuroSense Therapeutics
NRSN stock →NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
APRE vs NRSN FAQ
Which is bigger, Aprea Therapeutics or NeuroSense Therapeutics?
Aprea Therapeutics (APRE) is larger, with a market capitalization of $7.61M compared with $6.94M for NeuroSense Therapeutics (NRSN).
Are Aprea Therapeutics and NeuroSense Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.